ARVN vs. KYMR

In the year-to-date period, ARVN achieves a -4.49% return, which is significantly higher than KYMR's -8.33% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Arvinas, Inc. (ARVN) and Kymera Therapeutics, Inc. (KYMR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ARVN Sharpe Ratio is -1.10, which is lower than the KYMR Sharpe Ratio of 0.09. The chart below compares the historical Sharpe Ratios of ARVN and KYMR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ARVN nor KYMR has paid dividends to shareholders.

The maximum ARVN drawdown since its inception was -86.85%, roughly equal to the maximum KYMR drawdown of -87.51%. Use the drawdown chart below to compare losses from any high point for ARVN and KYMR. For additional features, visit the drawdowns tool.

The current volatility for Arvinas, Inc. (ARVN) is 15.17%, while Kymera Therapeutics, Inc. (KYMR) has a volatility of 16.73%. This indicates that ARVN experiences smaller price fluctuations and is considered to be less risky than KYMR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Arvinas, Inc. and Kymera Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.